Abstract
A rabbit VX2 colon cancer model with spontaneous liver metastases was used to evaluate the antitumor effect of an angiogenesis inhibitor, FR-118487. FR- 118487 (1 mg/kg/day) was infused continuously into the portal vein for a week after resection of primary colon cancer lesions (FR group). The incidence of liver metastases was 71.4% (5/7) in FR group, and 100% (7/7) in control group. The numher and the weight of liver metastatic nodules were 31.0±36.0 and 1.4±1.8 g in FR group versus 83.7±73.9 and 6.5±4.9 g in control group, respectively. The metastases in FR group were significantly decreased in weight compared with those in control group (p<0.05). No anastomotic leakage was recognized in either group. No side effects of FR-118487 such as body weight loss were found. Continuous intraportal infusion of FR-118487 in the early postoperative period may be effective to suppress liver metastases from colon cancer by inhibiting the angiogenesis concerning liver metastases.
| Original language | English |
|---|---|
| Pages (from-to) | 1480-1482 |
| Number of pages | 3 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 22 |
| Issue number | 11 |
| Publication status | Published - 1995 |
Keywords
- Colon cancer
- Continuous intraportal infusion
- FR-118487
- Liver metastasis
ASJC Scopus subject areas
- Medicine(all)
